Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination

Nipah virus (NiV) causes a highly lethal disease in humans who present with acute respiratory or neurological signs. No vaccines against NiV have been approved to date. Here, we report on the clinical impact of a novel NiV-derived nonspreading replicon particle lacking the fusion (F) protein gene (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Welch, Stephen R., Spengler, Jessica R., Genzer, Sarah C., Coleman-McCray, JoAnn D., Harmon, Jessica R., Sorvillo, Teresa E., Scholte, Florine E. M., Rodriguez, Sergio E., O’Neal, T. Justin, Ritter, Jana M., Ficarra, Georgia, Davies, Katherine A., Kainulainen, Markus H., Karaaslan, Elif, Bergeron, Éric, Goldsmith, Cynthia S., Lo, Michael K., Nichol, Stuart T., Montgomery, Joel M., Spiropoulou, Christina F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403222/
https://www.ncbi.nlm.nih.gov/pubmed/37540755
http://dx.doi.org/10.1126/sciadv.adh4057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403222/
https://www.ncbi.nlm.nih.gov/pubmed/37540755
http://dx.doi.org/10.1126/sciadv.adh4057

Ejemplares similares